Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration (ART-CC)

AIDS

Volumn 22, Issue 18, 2008, Pages 2481-2492

  Casabona, Jordi ^a   Chêne, Geneviève ^b   Del Amo, Julia ^c   Fätkenheuer, Gerd ^d,r   Guest, Jodie ^e   Kitahata, Mari ^d   Ledergerber, Bruno ^f   Mocroft, Amanda ^g   Reiss, Peter ^h   Mugavero, Michael J ⁱ   May, Margaret ^j   Harris, Ross ^j   Saag, Michael S ^k   Costagliola, Dominique ^l   Egger, Matthias ^m   Phillips, Andrew ⁿ   Günthard, Huldrych F ^k   Dabis, François ^o   Hogg, Robert ^p   De Wolf, Frank ^q   Gill, M John ^s   Justice, Amy ^t,u   Monforte, Antonella D'Arminio ^m   Lampe, Fiona ^v   Miró, Jose M ^w   Staszewski, Schlomo ^w   Sterne, Jonathan A C ^j   Dewolf, Frank ^d   more..

^a PISCIS   (Spain)

^b Aquitaine   (France)

^c CoRIS MD ^*  (United States)

^d HAVACS ^*

^e HAVACS   (United States)

^f SHC   (United States)

^g EuroSIDA   (United States)

^h ATHENA   (Italy)

ⁱ University of Alabama at Birmingham   (United States)

^j UNIVERSITY OF BRISTOL   (United Kingdom)

^k INSERM   (France)

^l UNIVERSITY OF BERN   (Switzerland)

^m ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^p ACADEMIC MEDICAL CENTER   (Netherlands)

^q UNIVERSITY OF COLOGNE   (Germany)

^r UNIVERSITY OF CALGARY   (Canada)

^s YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^u UNIVERSITY OF MILAN   (Italy)

^v UNIVERSITY OF BARCELONA   (Spain)

^w GOETHE UNIVERSITY   (Germany)

more..

Author keywords

AIDS; AIDS related opportunistic infections; Antiretroviral therapy; Cohort analysis; Highly active; HIV; Mortality; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT COURSE THERAPY;

EID: 57349102293     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328318f130     Document Type: Article

References (49)

1. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34.
2. Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006;20:67-71.
3. van Sighem Al, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003;17:2227-2236.
4. Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis 2006;194:542-544.
5. Walker AM. Confounding by indication. Epidemiology 1996;7:335-336.
6. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007;297:314-316.
7. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med 2007;356:1705-1707.
8. Smeeth L, Douglas I, Hubbard R. Commentary: we still need observational studies of drugs - they just need to be better. Int J Epidemiol 2006;35:1310-1311.
9. De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di Giambenedetto S, et al. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a nonrandomized comparison. Antivir Ther 2006;11:609-618.
10. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001;27:350-364.
11. Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, et al. Response to first protease inhibitor- and efavirenzcontaining antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2001;15:1793-1800.
12. Lucas CM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001;15:1679-1686.
13. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999;13:2075-2082.
14. Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, et al. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. Antivir Ther 2007;12:317-324.
15. Pulido F, Arribas JR, Miro JM, Costa MA, Gonzalez J, Rubio R, et al. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004;35:343-350.
16. Weiser SD, Guzman D, Riley ED, Clark R, Bangsberg DR. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials 2004;5:278-287.
17. Wood E, Hogg RS, Heath KV, de la Rosa R, Lee N, Yip B, et al. Provider bias in the selection of nonnucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 2003;17:2629-2634.
18. Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007;21:1579-1589.
19. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002;16:53-61.
20. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, et al. Viral load outcome of nonnucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviralexperienced patients. AIDS 2001;15:2385-2395.
21. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a nonnucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006;368:1503-1515.
22. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006;194:612-622.
23. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362:679-686.
24. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-129.
25. May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol 2005;58:1033-1041.
26. May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2004;23:2375-2398.
27. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
28. Binquet C, Chene G, Jacqmin-Gadda H, Journot V, Saves M, Lacoste D, Dabis F. Modeling changes in CD4-positive T- lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol 2001;153:386-393.
29. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790-798.
30. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I. CO. N. A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507.
31. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997;315:1194-1199.
32. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-1738.
33. Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113- F116.
34. Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:153-160.
35. Becker SL, Raffanti SR, Hansen Nl, Fusco JS, Fusco GP, Slatko GH, et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr 2001;26:72-81.
36. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006;42:1003-1010.
37. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006;44:S13-S24.
38. Mocroft A, Barry S, Sabin CA, Lepri AC, Kinloch S, Drinkwater A, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999;13:1255-1261.
39. Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, Schechter MT, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998;12:619-624.
40. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12:2161-2167.
41. Jaen A, Casabona J, Esteve A, Miro JM, Tural C, Ferrer E, et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc) 2005;124:525-531.
42. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. MMWR 1992;41:1-19.
43. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005;19:319-330.
44. Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG, Klingman KL, et al. A prospecitve randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-infection - ACTG 5142. In: Program and Abstracts of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. Abstract THLB0204.
45. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167:1782-1790.
46. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356.
47. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Cazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263.
48. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577.
49. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-1909.